Skinvisible Web Sign Up for Updates         T 702.433.7154
Skinvisible - Polymer Delivery System

The Ultimate Polymer Delivery System.
Skinvisible's value lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare. Skinvisible has numerous patents granted, including comprehensive trade secrets on Invisicare, the foundation of all of our products and products formulated with Invisicare. Additionally, Skinvisible has been granted three product-specific patents in the US for dermal barrier products, sunscreens (achieved 8-hour photostability of avobenzone) and retinoids (stabilization). Skinvisible has recently submitted a patent application for the "Transdermal Delivery Composition for Delivery CB-1 Receptor Antagonists and/or GPL-1 Receptor Agonist, and Method of Delivery," for the treatment of obesity which could be a game-changer in the multi-billion dollar obesity market. Skinvisible continues to seek patent opportunities in various markets where a topical or transdermal treatment would be effective.

Granted Patents

United States Patent No.:   8,318,818
Topical composition, topical composition precursor, and methods for manufacturing and using.

United States Patent No.:   9,149,490
Acne treatment composition and methods for using

United States Patent No.:   7,674,471
Topical composition, topical composition precursor, and methods for manufacturing and using.

United States Patent No.:   6,756,059
Topical composition, topical composition precursor, and methods for manufacturing and using.

United States Patent No.:   US8735422B2
Cationic pharmaceutically active ingredient containing composition, and methods for manufacturing and using.

United States Obesity Treatment Patent Application May 2024
Transdermal Delivery Composition for Delivery CB-1 Receptor Antagonists and/or GPL-1 Receptor Agonist, and Method of Delivery

Latest Press Releases:


May 21, 2024
Skinvisible files patent application for the transdermal treatment of obesity: "Transdermal Delivery Composition for Delivery CB-1 Receptor Antagonists and/or GPL-1 Receptor Agonist, and Method of Delivery."

February 14, 2024
Skinvisible Announces Significant Progress In Licensee's Clinical Trials For Invisicare Formulation Targeting Nethertons Syndrome

June 6, 2022
Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug Application



More News...



  Research & Development
  Technology Overview
Home    |     About us    |    Technology    |    Products    |    Investors    |    Contact Us    |    Disclaimer & Privacy    |     Sign Up for Updates
© 2008 Skinvisible Pharmaceuticals, Inc.     Note: This website is not intended for Canadian residents.